In a report released today, Joseph Stringer from Needham reiterated a Buy rating on Gilead Sciences, with a price target of $133.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Stringer has given his Buy rating due to a combination of factors including Gilead Sciences’ strong financial performance in the second quarter of 2025. The company reported earnings that exceeded both their own and consensus expectations, with total product sales reaching $7.05 billion, marking a 9% increase quarter-over-quarter and a 2% increase year-over-year. This growth was primarily driven by robust demand in their core HIV business, particularly from products like Biktarvy and Descovy, as well as contributions from their oncology segment with Trodelvy.
Furthermore, Gilead raised its total product sales guidance for 2025, reflecting confidence in continued strong performance, especially in the HIV segment. Stringer is particularly optimistic about the upcoming launch of Yeztugo for HIV PrEP, which is expected to further bolster the company’s market position. These positive developments underpin Stringer’s Buy rating and the reiterated price target of $133.
In another report released today, TD Cowen also maintained a Buy rating on the stock with a $115.00 price target.